{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:29:14Z","timestamp":1757618954074,"version":"3.44.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Intramural Project of the People's Hospital of Xinjiang Uygur Autonomous Region","award":["20200304"],"award-info":[{"award-number":["20200304"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04118-0","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T02:18:02Z","timestamp":1752805082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Yilihamu","family":"Abulitifu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mierzhati","family":"Maimaiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengcong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munire","family":"Adilijiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"6","key":"4118_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s12072-017-9830-1","volume":"11","author":"A Lleo","year":"2017","unstructured":"Lleo A, Marzorati S, Anaya JM, et al. Primary biliary cholangitis: a comprehensive overview. Hep Intl. 2017;11(6):485.","journal-title":"Hep Intl"},{"key":"4118_CR2","doi-asserted-by":"crossref","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6):e0179.","DOI":"10.1097\/HC9.0000000000000179"},{"key":"4118_CR3","first-page":"71","volume":"34\u201335","author":"J Ashnila","year":"2018","unstructured":"Ashnila J, Trivedi PJ. Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC). Best Pract Res Clin Gastroenterol. 2018;34\u201335:71\u201383.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"6","key":"4118_CR4","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","volume":"32","author":"C Corpechot","year":"2000","unstructured":"Corpechot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000;32(6):1196\u20139.","journal-title":"Hepatology"},{"issue":"12","key":"4118_CR5","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1586\/1744666X.2014.979792","volume":"10","author":"AH Ali","year":"2014","unstructured":"Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis. Expert Rev Clin Immunol. 2014;10(12):1667\u201378.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"4118_CR6","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/00365521.2020.1829030","volume":"55","author":"Z Wang","year":"2020","unstructured":"Wang Z, Peng C, Wang P, et al. Serum vitamin D level is related to disease progression in primary biliary cholangitis. Scand J Gastroenterol. 2020;55(11):1333\u201340.","journal-title":"Scand J Gastroenterol"},{"key":"4118_CR7","doi-asserted-by":"crossref","unstructured":"Ebadi M, Ip S, Lytvyak E et al. Vitamin D is associated with clinical outcomes in patients with primary biliary cholangitis. Nutrients. 2022;14(4):878.","DOI":"10.3390\/nu14040878"},{"issue":"3","key":"4118_CR8","first-page":"264","volume":"30","author":"Chinese Society of Hepatology, Chinese Medieal Association","year":"2022","unstructured":"Chinese Society of Hepatology, Chinese Medieal Association. Guidelines on the diagnosis and management of primary biliary cholangitis (2021). J Clin Hepatol. 2022;30(3):264\u201375.","journal-title":"J Clin Hepatol"},{"issue":"3","key":"4118_CR9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871\u20137.","journal-title":"Hepatology"},{"issue":"3","key":"4118_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130(3):715\u201320.","journal-title":"Gastroenterology"},{"issue":"11","key":"4118_CR11","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1136\/gut.2005.065862","volume":"54","author":"A Jacoby","year":"2005","unstructured":"Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54(11):1622\u20139.","journal-title":"Gut"},{"issue":"3","key":"4118_CR12","doi-asserted-by":"publisher","first-page":"e0301354","DOI":"10.1371\/journal.pone.0301354","volume":"19","author":"P .Bager","year":"2024","unstructured":".Bager P, Bossen L, Gantzel R, et al. High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial. PLoS ONE. 2024;19(3):e0301354.","journal-title":"PLoS ONE"},{"issue":"6","key":"4118_CR13","first-page":"860","volume":"28","author":"Y Liu","year":"2021","unstructured":"Liu Y, Tian S, Jia G, et al. Symptoms burden and Health-related quality of life in Chinese patients with primary biliary cholangitis. J Clin Transl Hepatol. 2021;28(6):860\u20137.","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"4118_CR14","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/jgh.15329","volume":"36","author":"T Lv","year":"2021","unstructured":"Lv T, Chen S, Li M, Zhang D, et al. Regional variation and Temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2021;36(6):1423\u201334.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"4118_CR15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s12072-019-09984-x","volume":"13","author":"N Zeng","year":"2019","unstructured":"Zeng N, Duan W, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol Int. 2019;13(6):788\u201399.","journal-title":"Hepatol Int"},{"issue":"9","key":"4118_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","volume":"3","author":"M Carbone","year":"2018","unstructured":"Carbone M, Nardi A, Flack S, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA response score. Lancet Gastroenterol Hepatol. 2018;3(9):626\u201334.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"4118_CR17","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","volume":"96","author":"JR Phillips","year":"2001","unstructured":"Phillips JR, Angulo P, Petterson T, et al. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol. 2001;96(9):2745\u201350.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"4118_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0016-5085(88)80029-5","volume":"95","author":"MM Kaplan","year":"1988","unstructured":"Kaplan MM, Elta GH, Furie B, et al. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology. 1988;95(3):787\u201392.","journal-title":"Gastroenterology"},{"issue":"4","key":"4118_CR19","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1053\/j.gastro.2008.12.040","volume":"136","author":"E D\u2019Aldebert","year":"2009","unstructured":"D\u2019Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, et al. Bile salts control the antimicrobial peptide Cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology. 2009;136(4):1435\u201343.","journal-title":"Gastroenterology"},{"issue":"12","key":"4118_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.autrev.2011.05.002","volume":"10","author":"E Peelen","year":"2011","unstructured":"Peelen E, Knippenberg S, Muris AH, et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev. 2011;10(12):733\u201343.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"4118_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","volume":"39","author":"AY Grigorian","year":"2015","unstructured":"Grigorian AY, Mardini HE, Corpechot C, et al. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39(3):296\u2013306.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"11","key":"4118_CR22","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Guo G, Zheng L, et al. Effectiveness of Fenofibrate in Treatment-Naive patients with primary biliary cholangitis: A randomized clinical trial. Am J Gastroenterol. 2023;118(11):1973\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"4118_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.4254\/wjh.v6.i12.901","volume":"6","author":"P Iruzubieta","year":"2014","unstructured":"Iruzubieta P, Ter\u00e1n \u00c1, Crespo J, F\u00e1brega E. Vitamin D deficiency in chronic liver disease. World J Hepatol. 2014;6(12):901\u201315.","journal-title":"World J Hepatol"},{"issue":"2","key":"4118_CR24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.23683","volume":"52","author":"N Al-Harthy","year":"2010","unstructured":"Al-Harthy N, Kumagi T, Coltescu C, et al. The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology. 2010;52(2):562\u201370.","journal-title":"Hepatology"},{"key":"4118_CR25","doi-asserted-by":"crossref","unstructured":"Kempinska-Podhorodecka A, Adamowicz M, Chmielarz M et al. Vitamin-D Receptor-Gene polymorphisms affect quality of life in patients with autoimmune liver diseases. Nutrients. 2020;12(8):2244.","DOI":"10.3390\/nu12082244"},{"issue":"12","key":"4118_CR26","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1136\/gut.2010.234666","volume":"60","author":"S Abramovitch","year":"2011","unstructured":"Abramovitch S, Dahan-Bachar L, Sharvit E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut. 2011;60(12):1728\u201337.","journal-title":"Gut"},{"issue":"1","key":"4118_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejim.2011.09.017","volume":"23","author":"S Isik","year":"2012","unstructured":"Isik S, Ozuguz U, Tutuncu YA, et al. Serum transforming growth factor-beta levels in patients with vitamin D deficiency. Eur J Intern Med. 2012;23(1):93\u20137.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"4118_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1440-1746.2002.02672.x","volume":"17","author":"M Neuman","year":"2002","unstructured":"Neuman M, Angulo P, Malkiewicz I, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol. 2002;17(2):196\u2013202.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"4118_CR29","doi-asserted-by":"publisher","first-page":"G112","DOI":"10.1152\/ajpgi.00132.2013","volume":"308","author":"S Abramovitch","year":"2015","unstructured":"Abramovitch S, Sharvit E, Weisman Y, et al. Vitamin D inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2015;308(2):G112-20.","journal-title":"Am J Physiol Gastrointest Liver Physiol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04118-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:47:29Z","timestamp":1757252849000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04118-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4118"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04118-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by Ethics Committee of People\u2019s Hospital of Xinjiang Uygur Autonomous Region (approval number: KY2021042007). All procedures were conducted in accordance with the ethical standards of the Helsinki Declaration. Participants gave informed consent to participate in the study before taking part. In cases where a participant was unable to sign the informed consent form personally due to limitations in behavioural capacity or other reasons, the informed consent form was signed by their guardian or authorised representative. Participants\u2019 records were anonymised and de-identified prior to analysis","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"525"}}